Bioresorbable Nano Hybrid Stent Based on a Magnesium Alloy and with the Capability of Controlled Drug Eluting to Treat Atherosclerosis of Heart Coronary Artery

Sadrneghad, SK; Sadeghabadi, A; Asefneghad, A; Hasanzadeh Nemati, N

Bioresorbable Nano Hybrid Stent Based on a Magnesium Alloy and with the Capability of Controlled Drug Eluting to Treat Atherosclerosis of Heart Coronary Artery

Authors

SK Sadrneghad ¹

A Sadeghabadi ²

A Asefneghad ³

N Hasanzadeh Nemati ³

¹ Professor of Engineering and Materials Science, Sanati Sharif University, Tehran, Iran

² Researcher in Medical Engineering, Islamic Azad University, Tehran Science and Research Branch, Faculty of Medical Sciences and Technologies

³ Assistant Professor, Department of Biomedical Engineering, Islamic Azad University, Tehran Science and Research Branch, Faculty of Medical Sciences and Technologies

Abstract

Coronary artery disease is the cause of most disabilities and deaths in the world. It has been more than two decades since stent technology was introduced and has proved to be useful in preventing coronary thrombosis and restenosis compared to balloon angioplasty. When permanent metal implant is used, this medical device would affect internal walls of blood vessels which would result in late healing process of endothelial. Delay in reconstruction of endothelial might lead to stent thrombosis. In recent years, drug eluting stents have played a revolutionary role in treating coronary artery diseases. These stents are invented to reduce risk of artery stenosis in treating coronary artery diseases. Drug delivery stents are important medical options for patients diagnosed with coronary artery disease and have been successful in suppressing uncontrollable neo-intima proliferation in response to successful stenting. Although improvement due to using drug eluting stents have had significant progress in reducing intra-stent restenosis compared to metallic bare stents, long term safety related to using these stents including location selection, high systemic irritant and stent late thrombosis still exists. However this complexity mechanism is still unknown. Therefore in order to solve the above-mentioned problems, bioresorbable scaffolds have been innovated to overcome this limitation. This equipment provides temporary scaffolds and they disappear as time goes by. These scaffolds are made of bioresorbable polymers and metallic alloys. The absorbed stent must carry out duty it is designed for in a specific time, have drug delivery and gradually absorbs in the body and disappears. Magnesium is an essential mineral material required for different physiological functions in human body. Magnesium alloy used in making this scaffold is bioresorbable and its strength to weight is comparable to strong steels. Hence, a magnesium scaffold has required radial strength to destroy atherosclerotic narrowing and is capable of keeping lumen coronary open. Moreover magnesium has antithrombogenic properties in bodies. In this study, their advantages and disadvantages have been investigated and bioresorbable stents and magnesium nano-hybrid stents will be introduced as a new method.

Keywords

Stent

Coronary Artery

Drug Delivery

Magnesium

Bioresorbable

1. Koshinas, K. C., Chatzizisis, Y. S, Antoniadis, A.P. and Giannoglon, G. D. "Role of Endothelial shear stress in stent Restenosis and implications for clinical translation". Journal of the American college of cardiology 59, 1337-1349, (2012).

2. R. Beyar, "Novel approaches to reduce restenosis", Ann. N. Y. Acad. sci. 1015 (2004), 367-378.

3. Hara, M. Nakamura, J.C. Palmaz, R.S. Schwartz, "Role of stent design and coatings on restenosis and thrombosis", Adv. drug del. Rev. 58(2006), 377-386.

4. I. Akin, H. Schneider, H. Ince, S. Kische, T. Rehders, T. Chatterjee, C. Nienaber" Second-and
third-generation drug-eluting coronary stents, Herz 36(2011), 190-197.

5. S. Chen, L. Tan, Y. Teng, B. Zhang, K. Yang, "Study of drug-eluting coating on metal coronary stent", Mater.sci.Eng.c33 (2013).

6. Acharya G., K. Park, Mechanism of controlled drug release from drug-eluting stents. Advanced Drug Delivery Reviews, 58, 387-401, (2006).

7. Finn, A.V., Nakazawa, G., Joner, M., Kolodgie, F.D., Mont E. K., Gold, H. K., Virmani, R., "Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing. Arteriosclerosis", Thrombosis, and Vascular Biology, 27, 1500-1510, (2007).

8. Foin N, Lee RD, Torii R, et al. Impact of stent strut design in metallic stents and biodegradable scaffolds. Int J Cardiol 2014; 177: 800-8.

9. Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol 2014; 64: 2541-51.

10. L Mao, L. Shen et al., Nanophasic biodegradation enhances the durability and biocompatibility of magnesium alloys for the next-generation vascular stents, Nanoscale 5(2013), 9517-9522.

11. Xu B. Firesorb PLLA-based sirolimus-eluting scaffold. Transcatheter Cardiovasc Therapeutics. Washington, DC. USA; October 31^st 2016.

12. Latib A, Fortitude, aptitude and magnitude: Other thin strut novel PLLA-based scaffolds. Bioresorbable vascular scaffolds at JIM 2017: a clinical workshop. JIM, Milan, Italy; February 14^th 2017.

13. Tenekecioglu E, Serruys PW, Onuma Y, et al. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Micofiber
Sirolimus-Eluting Scaffold Using Multimodality Imaging. JACC Cardiovasc Interv 2017; 10: 1115-30.

14. Lin mao et al, "A Promising biodegradable magnesium alloy suitable for clinical vascular stent application", scientific reports, 11 April 2017.

15. Lorenza petrini et al, "development of biodegradable magnesium alloy stents with coating", civil and environmental engineering department, politecnico di Milano, Italy 2014.

16. Vdani, M, Ge, Q, Wu, W., Petrini, l., "Texture effects on design of Mg biodegradable stents", International journal of material forming, 7(2014),
31-38.

17. Mp. sealy et al, "pulsed laser cutting of magnesium-calcium for biodegradable stents", Elsevier, Procedia CIRP42, (2016).

18. Carlos M. Campos et al, "bioresorbable
Drug-Eluting Magnesium-Alloy scaffold for treatment of coronary artery disease", International journal of molecular science,16 December 2013.

19. Kotaro Handa" Fabrication of Mg alloy tubes for biodegradable stent application" Materials science and engineering (2013).

20. Patel N, Banning Ap." Bioabsorbable scaffolds for the treatment of obstructive coronary artery disease: the next revolution in coronary intervention?" Heart 2013: 99: 1236-43.

21. Hwang, C. W., Wu, D., Edelman, E.R., "Impact of Transport and Drug Properties on the local pharmacology of Drug-Eluting Stents". International Journal of Cardiovascular Interventions, 5,
7-12, (2003).

22. Iqbal J, Serruys PW, Silber S, et al. Comparison of zotarolimus and everolimus eluting coronary stents: final 5-year report of the RESOLUTE all comers trial.Circ Cardiovasc Interv 2015; 8; e002230.

23. Baber, U. et al, "Impact of the Everlimus-Eluting stent on stent Thrombosis: A Meta-Analysis of 13 Randomized Trials". Journal of the American College of cardiology 58, 1569-1577, (2011).

24. Christiansen, E, H. et al, "Biolimus-eluting biodegradable polymer- coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention" (2013).

25. Muddin et al, "Surface treatments for controlling corrosion rate of biodegradable Mg and Mg-based alloy implants", school of engineering South Australia, September 2015.

26. Capodanno D, Gori T, NefH, et al. Percutaneous coronary intervention with everolimus eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicenter GHOST-EU registry. EuroIntervention 2015; 10: 1144-53.

27. Biotronik Press Release," BIOTRONIK Announces Positive 6-Month Results for DREAMS, the Pioneering Drug-Eluting Absorbable Metal Scaffold", 2011.